One-Year Outcomes of Intravitreal Bevacizumab (Avastin) Therapy for Polypoidal Choroidal Vasculopathy

Cheng, Cheng-Kuo; Peng, Chi‐Hsien; Chang, Chun‐Kai; Hu, Chi-Tan; Chen, Lee-Jen

doi:10.1097/iae.0b013e3181f84fdf

Cited by 51 publications

(35 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are fewer studies assessing the efficacy of bevacizumab, and most of them have short follow up duration or were not performed on treatment naïve patients [164,165,166,167,168,169,170,171]. In a retrospective case control study, Cho et al .…”

Section: Treatmentmentioning

confidence: 99%

Polypoidal Choroidal Vasculopathy in Asians

Wong

Cheung

2015

JCM

View full text Add to dashboard Cite

Age related macular degeneration (AMD) in Asians has been suggested to differ from their Western counterparts in terms of epidemiology, pathogenesis, clinical presentation and treatment. In particular, polypoidal choroidal vasculopathy (PCV) appears to be the predominant subtype of exudative AMD in Asian populations, in contrast to choroidal neovascularization secondary to AMD (CNV-AMD) in Western populations. Epidemiological data on PCV has been largely limited to hospital-based studies and there are currently no data on the incidence of PCV. Similarities and differences in risk factor profile between PCV and CNV-AMD point to some shared pathogenic mechanisms but also differential underlying mechanisms leading to the development of each phenotype. Serum biomarkers such as CRP, homocysteine and matrix metalloproteinases suggest underlying inflammation, atherosclerosis and deranged extracellular matrix metabolism as possible pathogenic mechanisms. In addition, recent advances in genome sequencing have revealed differences in genetic determinants of each subtype. While the standard of care for CNV-AMD is anti-vascular endothelial growth factor (VEGF) therapy, photodynamic therapy (PDT) has been the mainstay of treatment for PCV, although long-term visual prognosis remains unsatisfactory. The optimal treatment for PCV requires further clarification, particularly with different types of anti-VEGF agents and possible benefits of reduced fluence PDT.

show abstract

Section: Treatmentmentioning

confidence: 99%

Polypoidal Choroidal Vasculopathy in Asians

Wong

Cheung

2015

JCM

View full text Add to dashboard Cite

show abstract

“…2 Despite the similarities in the clinical features, the efficacy of treatment, including intravitreal anti-vascular endothelial growth factor (VEGF) therapy, is different between nAMD, which is a major subgroup of exudative AMD, and PCV. 4,5 This may reflect differences in their multifactorial pathogenesis, including associated systemic disorders, cigarette smoking, and genetic factors.…”

mentioning

confidence: 98%

Systemic Risk Factors Associated With Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration

Sakurada

Yoneyama

Imasawa

et al. 2013

Retina

View full text Add to dashboard Cite

show abstract

“…Retrospective studies with bevacizumab have shown favorable results in decreasing leakage and bleeding in eyes with PCV [13,14,15]. However, the BVN and the polyps persist in the majority of eyes, which may increase the risk of long-term recurrence of bleeding and exudation.…”

Section: Introductionmentioning

confidence: 99%

Polypoidal Choroidal Vasculopathy Exudation and Hemorrhage: Results of Monthly Ranibizumab Therapy at One Year

et al. 2013

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or hemorrhage. Methods: A prospective, single practice, open label trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV in 13 eyes of 13 patients who completed the 1-year study. The primary outcome measure was stabilization of vision (loss of <15 ETDRS letters). Secondary outcome measures included incidence of ocular and systemic adverse events, changes in subretinal hemorrhage, central foveal thickness, and polypoidal complexes on indocyanine green angiography at 1 year. Results: No patient lost ≥15 letters in visual acuity at 1 year. Three patients (23%) gained ≥15 letters at 12 months. Subretinal hemorrhage resolved in 9/9 eyes (100%). Macular edema improved in 5/5 eyes (100%). Subretinal fluid completely resolved in 4/9 eyes (44%), decreased in 2/9 eyes (22%), and increased in 3/9 eyes (33%). Polypoidal complexes decreased in 5/13 eyes (38%). Conclusion: Continuous monthly intravitreal ranibizumab decreases leakage and hemorrhage in eyes with exudative and hemorrhagic complications of PCV. Branching vascular networks persisted, and polypoidal complexes decreased in only 5/13 (38%) eyes with continuous antiangiogenic therapy at 1 year.

show abstract

One-Year Outcomes of Intravitreal Bevacizumab (Avastin) Therapy for Polypoidal Choroidal Vasculopathy

Abstract: Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography.

Cited by 51 publications

References 44 publications

Polypoidal Choroidal Vasculopathy in Asians

Polypoidal Choroidal Vasculopathy in Asians

Systemic Risk Factors Associated With Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration

Polypoidal Choroidal Vasculopathy Exudation and Hemorrhage: Results of Monthly Ranibizumab Therapy at One Year

Contact Info

Product

Resources

About